(Albany, US) DelveInsight launched its new report on Spinocerebellar Ataxias – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Spinocerebellar Ataxias – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Spinocerebellar Ataxias , historical and forecasted epidemiology as well as the Spinocerebellar Ataxias market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The key facts of the report:
1. Spinocerebellar Ataxia total Prevalent population in the seven major markets was 42,043 in 2017
2. Even the most common form of Spinocerebellar Ataxia in US populations (Spinocerebellar Ataxia3) is likely to test negative more than 99% of the time in a patient displaying ataxia without a family history.
Key benefits of the report:
1. Spinocerebellar Ataxia market report covers a descriptive overview and comprehensive insight of the Spinocerebellar Ataxia epidemiology and Spinocerebellar Ataxia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Spinocerebellar Ataxia market report provides insights on the current and emerging therapies.
3. Spinocerebellar Ataxia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Spinocerebellar Ataxia market report offers an edge that will help in developing business strategies by understanding trends moulding and leading the Spinocerebellar Ataxia market.
“Among the European five countries, Germany had the highest prevalent population of SCA, followed by the France, United Kingdom and Italy.”
The key players in Spinocerebellar Ataxia market are:
1. Biohaven Pharmaceuticals
2. Kissei Pharmaceuticals
The launch of the emerging therapies is expected to significantly impact the Spinocerebellar Ataxia treatment scenario in the upcoming years: –
Drugs covered
1. Troriluzole (BHV-4157)
2. KPS-0373 (Rovatirelin)
Table of contents:
1. Key Insights
2. Spinocerebellar Ataxia Market Overview at a Glance
3. Spinocerebellar Ataxia Disease Background and Overview
4. Spinocerebellar Ataxia Epidemiology and Patient Population
5. Country Wise-Epidemiology of Spinocerebellar Ataxia
5.1. United States
5.2. EU5 Countries
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Spinocerebellar Ataxia Treatments
7. Unmet Needs
8. Spinocerebellar Ataxia Emerging Therapies
8.1. Troriluzole: Biohaven Pharmaceuticals
8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical
9. Other Promising Candidates
9.1. IB1001: IntraBio
9.2. Stemchymal: Steminent Biotherapeutics
10. Spinocerebellar Ataxia 7 Major Market Analysis
11. The United States Market Outlook
11.1.United States Market Size
12. EU-5 Countries: Market Outlook
12.1.Germany
12.2. France
12.3. Italy
12.4. Spain
12.5. The United Kingdom
12.6.Japan: Market Outlook
12.7.Japan Market Size
13. Market Drivers
14. Market Barriers
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
Related reports:
Spinocerebellar Ataxia (SCA) – Epidemiology Forecast to 2030
Spinocerebellar Ataxias Pipeline Insight, 2020
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/